{"id":"nicotinyl-methylamide","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"A05AB01","category":"atc"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":["NCT01817751"],"aliases":[],"patents":[],"pricing":[],"allNames":"nicotinic acid methylamide","offLabel":[],"synonyms":["nicotinyl methylamide","nicotinic acid methylamide"],"timeline":[],"approvals":[],"brandName":"Nicotinic Acid Methylamide","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and the keys to these locks are special chemicals called neurotransmitters. Nicotinic Acid Methylamide is a key that fits into these locks, helping to send signals between cells. This can affect various bodily functions, but the exact way it works is still being studied.","oneSentence":"Nicotinic Acid Methylamide is thought to work by interacting with nicotinic acetylcholine receptors in the body.","technicalDetail":"Nicotinic Acid Methylamide is believed to act as an agonist at nicotinic acetylcholine receptors, which are a type of ionotropic receptor involved in neurotransmission."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4862","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nicotinyl methylamide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:57:19.352393","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"nicotinyl methylamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01817751","phase":"Phase 2","title":"Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Virginia Commonwealth University","isPivotal":false,"enrollment":47,"indication":"Glioblastoma, Recurrent Adult Brain Neoplasm","completionDate":"2023-05-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"X3I82S5L8I","CHEBI":"CHEBI:64399","UMLSCUI":"C3652544","ChEMBL_ID":"CHEMBL11978","DRUGBANK_ID":"DB08840","PDB_CHEM_ID":"PJH","PUBCHEM_CID":"77116"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"A05AB01","allCodes":["A05AB01"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Nicotinic Acid Methylamide, also known as nicotinyl methylamide, is a small molecule modality with unknown drug class and target. Its commercial status is currently unknown, and it has not been approved by the FDA for any indications. As a research compound, it is still in the early stages of development. Further information on its pharmacokinetics, safety, and efficacy is not available. As a result, it is not yet available as a prescription medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}